PL3630098T3 - Połączenie antagonisty receptora 5-ht6 i inhibitora acetylocholinoesterazy do zastosowania w leczeniu choroby alzheimera w subpopulacji pacjentów posiadających allele apoe4 - Google Patents
Połączenie antagonisty receptora 5-ht6 i inhibitora acetylocholinoesterazy do zastosowania w leczeniu choroby alzheimera w subpopulacji pacjentów posiadających allele apoe4Info
- Publication number
- PL3630098T3 PL3630098T3 PL18726791T PL18726791T PL3630098T3 PL 3630098 T3 PL3630098 T3 PL 3630098T3 PL 18726791 T PL18726791 T PL 18726791T PL 18726791 T PL18726791 T PL 18726791T PL 3630098 T3 PL3630098 T3 PL 3630098T3
- Authority
- PL
- Poland
- Prior art keywords
- alzheimer
- disease
- treatment
- combination
- receptor antagonist
- Prior art date
Links
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 title 1
- 108700028369 Alleles Proteins 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 239000000544 cholinesterase inhibitor Substances 0.000 title 1
- 239000003751 serotonin 6 antagonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201700313 | 2017-05-24 | ||
DKPA201700538 | 2017-09-29 | ||
EP18726791.9A EP3630098B1 (en) | 2017-05-24 | 2018-05-22 | Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles |
PCT/EP2018/063402 WO2018215478A1 (en) | 2017-05-24 | 2018-05-22 | Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3630098T3 true PL3630098T3 (pl) | 2021-09-06 |
Family
ID=62235961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL18726791T PL3630098T3 (pl) | 2017-05-24 | 2018-05-22 | Połączenie antagonisty receptora 5-ht6 i inhibitora acetylocholinoesterazy do zastosowania w leczeniu choroby alzheimera w subpopulacji pacjentów posiadających allele apoe4 |
Country Status (22)
Country | Link |
---|---|
US (1) | US11464759B2 (pl) |
EP (1) | EP3630098B1 (pl) |
JP (1) | JP7167065B2 (pl) |
KR (1) | KR102676011B1 (pl) |
CN (1) | CN111032038A (pl) |
AU (1) | AU2018272883B2 (pl) |
BR (1) | BR112019001145A2 (pl) |
CA (1) | CA3063968A1 (pl) |
CY (1) | CY1124282T1 (pl) |
DK (1) | DK3630098T3 (pl) |
ES (1) | ES2869128T3 (pl) |
HR (1) | HRP20210634T1 (pl) |
HU (1) | HUE053636T2 (pl) |
LT (1) | LT3630098T (pl) |
MX (1) | MX2019013912A (pl) |
PL (1) | PL3630098T3 (pl) |
PT (1) | PT3630098T (pl) |
RS (1) | RS61704B1 (pl) |
SG (1) | SG11201909895UA (pl) |
SI (1) | SI3630098T1 (pl) |
WO (1) | WO2018215478A1 (pl) |
ZA (1) | ZA201907525B (pl) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE372768T1 (de) | 2001-03-29 | 2007-09-15 | Lilly Co Eli | N-(2-arylethyl) benzylamine als 5-ht6 rezeptor- antagoniste |
PT1529116E (pt) * | 2002-08-07 | 2009-09-10 | Novartis Ag | Métodos para o tratamento da demência com base no genótipo da apo e |
WO2008143361A1 (en) | 2007-05-22 | 2008-11-27 | Otsuka Pharmaceutical Co., Ltd. | A medicament comprising a carbostyril derivative and donepezil for treating alzheimer's disease |
WO2009074607A1 (en) | 2007-12-12 | 2009-06-18 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
RU2369600C1 (ru) * | 2008-01-24 | 2009-10-10 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 4-СУЛЬФОНИЛ-ПИРАЗОЛЫ И 3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ5-HT6 РЕЦЕПТОРОВ, АКТИВНЫЙ КОМПОНЕНТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЛЕКАРСТВЕННОЕ СРЕДСТВО И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
US8404711B2 (en) | 2009-04-13 | 2013-03-26 | Theravance, Inc. | 5-HT4 receptor agonist compounds for treatment of cognitive disorders |
WO2014165701A1 (en) | 2013-04-03 | 2014-10-09 | The University Of Utah Research Foundation | Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
JO3459B1 (ar) | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
JP2018519358A (ja) | 2015-05-07 | 2018-07-19 | アクソファント サイエンシーズ ゲーエムベーハーAxovant Sciences Gmbh | 神経変性疾患を処置する方法 |
RU2742173C2 (ru) * | 2016-04-26 | 2021-02-02 | Х. Лундбекк А/C | Применение ингибитора ацетилхолинэстеразы и идалопирдина для снижения риска падений у пациентов с болезнью паркинсона |
US10864191B2 (en) * | 2016-05-11 | 2020-12-15 | H. Lundbeck A/S | 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity |
-
2018
- 2018-05-22 SG SG11201909895U patent/SG11201909895UA/en unknown
- 2018-05-22 WO PCT/EP2018/063402 patent/WO2018215478A1/en active Application Filing
- 2018-05-22 DK DK18726791.9T patent/DK3630098T3/da active
- 2018-05-22 CN CN201880033314.8A patent/CN111032038A/zh active Pending
- 2018-05-22 JP JP2019564834A patent/JP7167065B2/ja active Active
- 2018-05-22 EP EP18726791.9A patent/EP3630098B1/en active Active
- 2018-05-22 CA CA3063968A patent/CA3063968A1/en active Pending
- 2018-05-22 SI SI201830258T patent/SI3630098T1/sl unknown
- 2018-05-22 ES ES18726791T patent/ES2869128T3/es active Active
- 2018-05-22 AU AU2018272883A patent/AU2018272883B2/en active Active
- 2018-05-22 MX MX2019013912A patent/MX2019013912A/es unknown
- 2018-05-22 PT PT187267919T patent/PT3630098T/pt unknown
- 2018-05-22 RS RS20210449A patent/RS61704B1/sr unknown
- 2018-05-22 HU HUE18726791A patent/HUE053636T2/hu unknown
- 2018-05-22 KR KR1020197032218A patent/KR102676011B1/ko active IP Right Grant
- 2018-05-22 BR BR112019001145-5A patent/BR112019001145A2/pt active Search and Examination
- 2018-05-22 LT LTEP18726791.9T patent/LT3630098T/lt unknown
- 2018-05-22 PL PL18726791T patent/PL3630098T3/pl unknown
- 2018-05-23 US US15/987,449 patent/US11464759B2/en active Active
-
2019
- 2019-11-13 ZA ZA2019/07525A patent/ZA201907525B/en unknown
-
2021
- 2021-04-14 CY CY20211100328T patent/CY1124282T1/el unknown
- 2021-04-22 HR HRP20210634TT patent/HRP20210634T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
CY1124282T1 (el) | 2022-07-22 |
EP3630098B1 (en) | 2021-03-24 |
SG11201909895UA (en) | 2019-11-28 |
SI3630098T1 (sl) | 2021-07-30 |
LT3630098T (lt) | 2021-05-25 |
EP3630098A1 (en) | 2020-04-08 |
HUE053636T2 (hu) | 2021-07-28 |
RU2019135609A (ru) | 2021-06-24 |
HRP20210634T1 (hr) | 2021-05-28 |
JP7167065B2 (ja) | 2022-11-08 |
AU2018272883B2 (en) | 2024-02-15 |
DK3630098T3 (da) | 2021-04-26 |
KR102676011B1 (ko) | 2024-06-17 |
US11464759B2 (en) | 2022-10-11 |
MX2019013912A (es) | 2020-01-21 |
US20180353477A1 (en) | 2018-12-13 |
RS61704B1 (sr) | 2021-05-31 |
AU2018272883A1 (en) | 2019-11-14 |
WO2018215478A1 (en) | 2018-11-29 |
CN111032038A (zh) | 2020-04-17 |
PT3630098T (pt) | 2021-04-21 |
BR112019001145A2 (pt) | 2019-04-30 |
ES2869128T3 (es) | 2021-10-25 |
KR20200007795A (ko) | 2020-01-22 |
RU2019135609A3 (pl) | 2021-08-23 |
CA3063968A1 (en) | 2018-11-29 |
JP2020520964A (ja) | 2020-07-16 |
ZA201907525B (en) | 2022-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL3577135T3 (pl) | Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5 | |
EP3829628C0 (en) | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OR PREVENTION OF C5-RELATED DISEASE | |
GB201917974D0 (en) | Apparatus and system for measuring one or more parameters of a person's foot | |
SG11202004408YA (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
PH12017502099A1 (en) | Methods for diagnosing and assessing treatment for cushing's syndrome | |
IL264040A (en) | An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients | |
IL284175A (en) | Dosing regimens in the use of LY3154207 in the treatment of diseases of the dopaminergic central nervous system | |
IL262546B (en) | Use of an acetylcholinesterase inhibitor and idalopyridine to reduce falls in Parkinson's patients | |
PT3937948T (pt) | Fitoecdisonas e seus derivados para utilização no tratamento de doenças neuromusculares | |
ZA201907525B (en) | Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles | |
IL272495A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
MX2018014184A (es) | Triple combinacion de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda. | |
PT3648761T (pt) | Telmisartan para a profilaxia ou tratamento de hipertensão em gatos | |
PT3600276T (pt) | Beta-histina, ou um seu sal farmaceuticamente aceitável, e um inibidor da monoamina oxidase, para utilização no tratamento ou prevenção de um ou mais sintomas de vertigem num indivíduo | |
SG10201801200PA (en) | An h3 receptor antagonist for use in the treatment of alzheimer's disease | |
PL3413870T3 (pl) | Igmezyna do zastosowania do leczenia choroby alzheimera | |
IL267716A (en) | Drug combination therapies that use drugs designed for bone and bone-related diseases | |
IL271795A (en) | A screening platform to identify drugs or medical substances for the treatment of Alzheimer's disease | |
GB201718838D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
GB201712742D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases |